PARP inhibitors
Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development
The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.
KSQ Therapeutics Begins Trial of USP1 Inhibitor for Advanced Solid Tumors
Through a Phase I trial, the firm will study KSQ-4279 both alone and in combination with other drugs, and look for biomarkers predictive of patient response.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer
The guideline comes in the wake of the OlympiA trial results, which showed that the PARP inhibitor significantly improved invasive disease-free survival.
Edison Oncology, Rakovina Therapeutics Partner on PARP Inhibitor Program
Edison has transferred ownership of its PARP inhibitor program to Rakovina in exchange for 43 percent of outstanding common shares in the firm.